Research programme: p53 upregulated modulator of apoptosis stimulants - ArQule

Drug Profile

Research programme: p53 upregulated modulator of apoptosis stimulants - ArQule

Alternative Names: ARQ-850RP; Research programme: PUMA stimulants - ArQule

Latest Information Update: 11 Apr 2011

Price : $50

At a glance

  • Originator ArQule
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 31 May 2006 This programme is still in active development
  • 31 Aug 2005 Preclinical trials in Solid tumours in USA (unspecified route)
  • 16 Sep 2003 Cyclis Pharmaceuticals has been acquired by, and merged into, ArQule
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top